【レポートの概要（一部）】
1. Introduction to CD Antigens
2. Nomenclature & Classification of CD Antigens
3. Mechanism of CD Antigen Cancer Therapeutics
4. Cancer CD Antigen Therapy Market Overview
4.1 Current Scenario
4.2 Cancer CD Antigen Inhibitors Pipeline Overview
5. CD Antigen Cancer Market Dynamics
5.1 Favorable Market Parameters
5.2 Commercialization Challenges
6. CD Antigen Cancer Therapeutics Future Prospects
7. Cancer CD Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
7.1 Phase-I/II
8. Cancer CD3 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
8.1 Preclinical till Phase-II
9. Cancer CD4 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
9.1 Phase-II
10. Cancer CD9 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
10.1 Preclinical
11. Cancer CD11 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
11.1 Preclinical
12. Cancer CD19 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
12.1 Phase-I till Phase-II
13. Cancer CD20 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
13.1 Research till Phase-III
13.2 Marketed CD20 Antigen Inhibitors Drug Clinical Insight
14. Cancer CD22 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
14.1 Phase-II till Phase-III
15. Cancer CD26 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
15.1 Preclinical till Phase-I/II
16. Cancer CD27 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
16.1 Research till Phase-I/II
17. Cancer CD28 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
17.1 Preclinical
18. Cancer CD29 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
18.1 Preclinical
19. Cancer CD33 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
19.1 Phase-I till Phase-I/II
19.2 Marketed CD33 Antigen Inhibitors Drug Clinical Insight
20. Cancer CD37 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
20.1 Phase-I till Phase-II
21. Cancer CD38 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
21.1 Research till Preregistration
22. Cancer CD40 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
22.1 Phase-I
23. Cancer CD44 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
23.1 Preclinical
24. Cancer CD45 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
24.1 Preclinical till Phase-II
25. Cancer CD47 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
25.1 Preclinical till Phase-I
26. Cancer CD52 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
26.1 Research till Preclinical
26.2 Marketed CD52 Antigen Inhibitors Drug Clinical Insight
27. Cancer CD55 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
27.1 Preclinical till Phase-II
28. Cancer CD56 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
28.1 Preclinical till Phase-II
29. Cancer CD66 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
29.1 Preclinical till Phase-II
30. Cancer CD70 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
30.1 Phase-I
31. Cancer CD74 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
31.1 Preclinical till Phase-I/II
32. Cancer CD80 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
32.1 Preclinical till Phase-II
33. Cancer CD95 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
33.1 Preclinical
34. Cancer CD98 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
34.1 Phase-I
35. Cancer CD100 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
35.1 Phase-I
36. Cancer CD117 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
36.1 Preclinical till Phase-III
36.2 Marketed CD117 Antigen Inhibitors Drug Clinical Insight
37. Cancer CD135 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
37.1 Preclinical till Phase-III
37.2 Marketed CD135 Antigen Inhibitors Drug Clinical Insight
38. Cancer CD137 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
38.1 Preclinical
39. Cancer CD152 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
39.1 Marketed CD152 Antigen Inhibitors Drug Clinical Insight
40. Cancer CD200 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
40.1 Preclinical
41. Cancer CD223 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
41.1 Research till Phase-I
42. Cancer CD227 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
42.1 Phase-I till Phase-II
43. Cancer CD246 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
43.1 Preclinical till Phase-II
43.2 Marketed CD246 Antigen Inhibitors Drug Clinical Insight
44. Cancer CD248 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
44.1 Phase-II
45. Cancer CD274 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
45.1 Research till Phase-III
45.2 Marketed CD274 Antigen Inhibitors Drug Clinical Insight
46. Cancer CD276 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
46.1 Phase-I
47. Cancer CD279 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
47.1 Phase-I till Phase-II
47.2 Marketed CD279 Antigen Inhibitors Drug Clinical Insight
48. Multiple Cancer CD Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
48.1 Preclinical till Phase-III
48.2 Marketed Multiple CD Antigen Inhibitors Drug Clinical Insight
49. Discontinued & Suspended Cancer CD Antigen Inhibitors Drug Clinical Insight
49.1 No Development Reported
49.2 Discontinued
49.3 Market Withdrawal
49.4 Suspended
50. Competitive Landscape
50.1 Alexion Pharmaceuticals
50.2 ARIAD Pharmaceuticals
50.3 AryoGen Biopharma
50.4 AXXO
50.5 Bayer HealthCare
50.6 Biocad
50.7 Biogen
50.8 Biotecnol Inc.
50.9 Bristol-Myers Squibb
50.10 Chugai Pharmaceutical
50.11 Dr Reddy’s Laboratories
50.12 Eisai Co Ltd
50.13 Emergent BioSolutions
50.14 Genmab
50.15 ImmunoGen
50.16 Intas Biopharmaceuticals
50.17 MacroGenics
50.18 MedImmune
50.19 Merck
50.20 Novartis
50.21 Ono Pharmaceutical
50.22 Onyx Pharmaceuticals
50.23 Pfizer
50.24 PROBIOMED
50.25 Roche
50.26 UCB
50.27 Xencor
【レポート販売概要】
■ タイトル：がんCD抗原阻害剤の世界市場及びパイプライン2015■ 英文：Cancer CD Antigens Inhibitors Therapy Market & Pipeline Insight 2015
■ 発行日：42217
■ 調査会社：KuicK Research
■ 商品コード：KUIK51101
■ 調査対象地域：グローバル
- ゼオライト（沸石）の世界市場動向2014/2015The report presents a thorough study of zeolites, covering both global and regional markets. It aims to give a proper picture of the market, its trends, perspectives and opportunities. Comprehensive data showing zeolites worldwide production, consumption, trade statistics and prices are provided. Each country’s market overview covers the following: zeolites production in the country, major manufac …
- 幹細胞治療の世界市場2018-2022About Stem Cell Therapy Stem cells are cells that have the ability to divide and differentiate into almost every cell type in the body and used in surgery and medicine. Technavio’s analysts forecast the Global Stem Cell Therapy Market to grow at a CAGR of 10.52% during the period 2018-2022. Covered in this report The report covers the present scenario and the growth prospects of the stem cell ther …
- BSN medical GmbH：市場シェア分析BSN medical GmbH Market Share Analysis Summary GlobalData’s new report, “BSN medical GmbH Market Share Analysis” provides in-depth information on BSN medical GmbH’s market position in the different medical equipment markets it operates in. The report provides BSN medical GmbH market share information in four key market categories – Orthopedic Bone Cement and Casting Materials, Orthopedic Braces an …
- 研磨パッドの世界市場2017-2021About Sanding PadSanding pads are coated abrasives that are used for various commercial and industrial sanding purposes. They are attached to devices called sanders, which use sandpaper as an abrasive. Sanding pads are used to smoothen and polish surfaces. Sanding pads consist of a sandpaper, a type of coated abrasive, which is attached to a backing of fiber, plastic, paper, or sponge. These are u …
- Market Opportunity: Call Continuity in Voice over LTE (VoLTE)Fourth generation (4G) data services are in the deployment stage, but is will be a few years until there is ubiquitous LTE coverage. Meanwhile, there are competitive threats emerging against incumbent carriers’ core voice services. This is coming at a time when all bearer services (voice and data) are becoming marginalized due to market expectations, economic conditions, and a coming supply side e …
- Enerplus Corporation：石油・ガスバリューチェーン分析レポート2013Enerplus Corporation Analysis Across the Oil and Gas Value Chain Report, 2013 Update Summary "Enerplus Corporation" Analysis Across the Oil and Gas Value Chain is an essential source for data, analysis and strategic insight into “Enerplus Corporation”. The report provides key information relating to oil and gas assets of the company along with its operations across the value chain. The report exam …
- アスファルトの世界市場：舗装、ルーフィング用途About Asphalt Asphalt is a binder and filler; it is a refined residue obtained from the distillation process of some specific petroleum-refined crude oils. It is primarily used in road construction for binding and is normally mixed with aggregate particles for creating asphalt concrete. The aggregate particles used in asphalt mixtures mainly consist of rock, sand, gravel, or slag. Asphalt finds it …
- 脳脊髄炎（Encephalomyelitis）：グローバル臨床試験動向（2014年上半期）Encephalomyelitis Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Encephalomyelitis Global Clinical Trials Review, H1, 2014" provides data on the Encephalomyelitis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Encephalomyelitis. It includes an overview of the trial numbers and their recruitment s …
- キーレスエントリーシステムの世界市場ABSTRACTAbout Keyless Entry Systems Keyless entry systems are systems that provide physical access to a premise without using a mechanical key to perform locking and unlocking operations. These systems provide enhanced security and convenience for users. Users get authorized and secure access to a premise by using a device such as a smart card or a keyless fob, or by using their own fingerprints, …
- 医療レポート：Diabetic Neuropathy-疫学予測（～2022）EpiCast Report: Diabetic Neuropathy - Epidemiology Forecast to 2022 Summary Diabetic neuropathy affects an estimated 50% of patients with diabetes and is one of the leading causes of morbidity in diabetic patients, often leading to foot ulcerations or amputation. Diabetic neuropathy is clinically defined as “the presence of symptoms and/or signs of peripheral nerve dysfunction in people with diabe …
- Red Mountain Resources Inc.社の石油・ガス開発・生産動向及びコスト分析（2013年）Red Mountain Resources Inc. Oil & Gas Exploration and Production Operations and Cost Analysis - 2013 Summary Red Mountain Resources Inc. Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essentia …
- 世界の合成ガス（Syngas）市場動向（2014～2018）TechNavio's analysts forecast the Global Syngas market to grow at a CAGR of 8.54 percent over the period 2013-2018. One of the key factors contributing to this market growth is the flexibility in feedstock for production. The Global Syngas market has also been witnessing increasing investments in R&D. However, the increase in vendor competition could pose a challenge to the growth of this market. …
- 感圧接着剤の世界市場：水系接着剤、溶剤系接着剤、ホットメル接着剤、放射線硬化型感圧接着剤About Pressure-sensitive Adhesives Pressure-sensitive adhesives are a category of adhesives that form a bond with the substrate on the application of slight pressure. They provide a strong and durable bond for lightly loaded applications. Pressure-sensitive adhesives are used in a wide range of applications, from automotive to medical and general industrial applications. The four major types of pr …
- ベースオイルの世界市場分析：製品別（グループ1、グループ2、グループ3）、用途別（自動車用オイル、プロセスオイル、油圧オイル、金属加工用流体、工業オイル）セグメント予測The global base oil market is expected to reach USD 40.47 billion by 2024, according to a new report by Grand View Research, Inc. Growing demand for industrial lubricants, greases, hydraulic fluids, and metal working fluids made from raw stock fluids such as base oil is anticipated to remain a key driving factor for the market growth. The shifting trend towards adoption of Group II and Group III b …
- LTEネットワーク上の無線セキュリティ市場2013-2018（Wireless Security Market in LTE Networks 2013-2018）With the rapid expansion of broadband wireless, end-users increasingly rely upon handheld devices for almost all daily living activities. Fourth generation (4G) cellular LTE in particular represents a unique opportunity/challenge as device attacks are growing at a rapid rate, exposing vulnerabilities that must be addressed. Our research indicates that Android malware in particular will grow rapidl …
